Slate Medicines

Slate Bio is a preclinical-stage biotechnology company developing a new class of bifunctional protein therapeutics designed to induce immunological tolerance. The company's lead program is a first-in-class IL-2/IL-10 fusion protein that selectively targets and expands regulatory T cells (Tregs) while simultaneously suppressing inflammatory effector T cells. This dual-action approach aims to treat a wide range of autoimmune and inflammatory diseases by restoring immune balance. Slate Bio's platform is based on research from the University of Pittsburgh and is supported by a syndicate of leading life science investors. The company is headquartered in Philadelphia and is advancing its lead candidate toward clinical development.